Harvard Bioscience (HBIO) Misses Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.60 -3.37%
Revenue Growth %: +6.1%
Financial Fact:
Income tax expense: 758K
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +6.1%
Financial Fact:
Income tax expense: 758K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $23.7 million versus the consensus estimate of $23.1 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- EverQuote (EVER) Tops Q3 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
